阿比多尔联合连花清瘟胶囊治疗新型冠状病毒肺炎的临床观察  

Clinical study on combined scheme of Lianhuaqingwen Capsules and abidole in the treatment for coronavirus disease 2019

作　　者：柳丽丽[1] 袁连方 冯毅[3] 孙东 刘文生[1] 王毅军[5] 任超逸[5] LIU Li-li;YUAN Lian-fang;FENG Yi;SUN Dong;LIU Wen-sheng;WANG Yi-jun;REN Chao-yi(Department of Pharmacy,the Third Central Hospital of Tianjin,Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases,Artificial Cell Engineering Technology Research Center,Tianjin Institute of Hepatobiliary Disease,Tianjin 300170,China;不详)

机构地区：[1]天津市第三中心医院、天津市重症疾病体外生命支持重点实验室、天津市人工细胞工程技术研究中心、天津市肝胆研究所药剂科,天津300170 [2]国家卫生健康委员会激素与发育重点实验室(天津医科大学)、天津市代谢性疾病重点实验室、天津医科大学朱宪彝纪念医院、天津市内分泌研究所呼吸内科,天津300134 [3]天津市第五中心医院、北京大学滨海医院泌尿外科,天津300450 [4]天津医科大学一中心临床学院,天津300192 [5]天津市第三中心医院、天津市重症疾病体外生命支持重点实验室、天津市人工细胞工程技术研究中心、天津市肝胆研究所肝外科,天津300170

出　　处：《广东医学》2020年第12期1207-1210,共4页Guangdong Medical Journal

基　　金：天津市科技计划项目(17YFZCSY01070)。

摘　　要：目的探讨阿比多尔联合连花清瘟胶囊治疗新型冠状病毒肺炎(COVID-19)的疗效及安全性。方法回顾分析32例COVID-19患者的临床资料,分为A+L组18例和L组14例。A+L组予阿比多尔联合连花清瘟胶囊治疗,L组予单纯服用连花清瘟胶囊治疗。统计患者住院期间主要临床干预措施的使用例数及比例,记录住院期间的临床结局,统计各观察指标及肝功能异常率。结果两组治疗过程中转成危重症病例各1例。A+L组肝功能异常14例(77.78%),L组8例(57.14%)。A+L组使用抗菌药物17例(94.44%),L组13例(92.86%)。A+L组使用糖皮质激素10例(55.56%),L组9例(64.29%)。与L组比较,A+L组的体温恢复正常时间(t=-2.471,P=0.019)、呼吸道症状明显好转时间(t=-2.918,P=0.007)、胸部CT显示炎症明显吸收时间(t=-2.937,P=0.006)、连续2次病毒核酸转阴时间(t=-2.930,P=0.006)、住院时间(t=-2.785,P=0.009)均显著缩短,差异有统计学意义。结论阿比多尔联合连花清瘟胶囊可用于COVID-19患者的治疗,耐受性良好,能够有效缩短患者住院时间及治疗时间,值得临床推广。Objective To investigate the efficacy and safety of abidor combined with Lianhuaqingwen Capsules on the treatment of coronavirus disease 2019(COVID-19).Methods The clinical data of 32 COVID-19 patients were retrospectively analyzed.The patients were divided into 2 groups,Group A+L,in which 18 patients received treatment of abidor combined with Lianhuaqingwen Capsules;and Group L,in which 14 patients received treatment of Lianhuaqingwen Capsules alone.The clinical intervention and indexes,and prognosis were analyzed and compared.Results In the course of treatment,there were 1 critical case in each group.The abnormal liver function was observed in 14 cases(77.78%)in the Group A+L and 8 cases(57.14%)in the Group L.Antibiotics treatment was performed in 17 cases(94.44%)in the Group A+L and 13 cases(92.86%)in the Group L.Glucocorticoid use was reported in 10 cases(55.56%)in the Group A+L and 9 cases(64.29%)in the Group L.Compared with Group L,Group A+L significantly shortened recovery duration in temperature(t=2.471,P=0.019),recovery duration in respiratory symptoms(t=2.918,P=0.007),chest CT inflammation absorption duration(t=2.937,P=0.006),negative 2 consecutive virus nucleic acid tests duration(t=2.930,P=0.006),and hospital stay(t=-2.785,P=0.009)were observed in Group A+L.Conclusion Abidor combined with Lianhuaqingwen Capsules can be used to treat COVID-19,with good tolerance,shorten the course of treatment for patients.

关 键 词：新型冠状病毒肺炎 阿比多尔 连花清瘟胶囊 中西医治疗 抗病毒治疗 

分 类 号：R-332[医药卫生] R826.64